These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36113491)

  • 1. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
    Danese S; Ferrante M; Feagan BG; Peyrin-Biroulet L; Hibi T; Sandborn WJ; Schreiber S; Ritter T; Loftus EV; Rogler G; Oortwijn A; Yun C; Le Brun FO; Dinoso J; Hsieh J; Vermeire S
    Am J Gastroenterol; 2023 Jan; 118(1):138-147. PubMed ID: 36113491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.
    Schreiber S; Feagan BG; Peyrin-Biroulet L; Vermeire S; Faes M; Harris K; Oortwijn A; Daniele P; Patel H; Danese S
    J Crohns Colitis; 2023 Jun; 17(6):863-875. PubMed ID: 36756874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
    Vermeire S; Feagan BG; Peyrin-Biroulet L; Oortwijn A; Faes M; de Haas A; Rogler G
    J Crohns Colitis; 2024 Jan; 18(1):54-64. PubMed ID: 37540206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
    Feagan BG; Matsuoka K; Rogler G; Laharie D; Vermeire S; Danese S; Loftus EV; Beales I; Schreiber S; Kim HJ; Faes M; de Haas A; Masior T; Rudolph C; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2024 Sep; 60(5):563-584. PubMed ID: 39086130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.
    Watanabe K; Peyrin-Biroulet L; Danese S; Fujitani Y; Faes M; Oortwijn A; Lindsay JO; Rogler G; Hibi T
    J Crohns Colitis; 2024 Jun; 18(6):801-811. PubMed ID: 38019901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
    Hibi T; Motoya S; Hisamatsu T; Hirai F; Watanabe K; Matsuoka K; Saruta M; Kobayashi T; Feagan BG; Tasset C; Besuyen R; Yun C; Crans G; Zhang J; Kondo A; Watanabe M
    Intest Res; 2023 Jan; 21(1):110-125. PubMed ID: 35263963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
    Loftus EV; Vermeire S; Feagan BG; Le Brun FO; Oortwijn A; Moerch U; Sandborn WJ; Hibi T
    J Crohns Colitis; 2023 Mar; 17(2):211-220. PubMed ID: 36006011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
    Dotan I; Feagan BG; Taliadouros V; Oortwijn A; Rudolph C; de Haas A; Santermans E; Hsieh J; Peyrin-Biroulet L; Hibi T
    J Crohns Colitis; 2023 Aug; 17(8):1207-1216. PubMed ID: 36928705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
    Loftus EV; Colombel JF; Takeuchi K; Gao X; Panaccione R; Danese S; Dubinsky M; Schreiber S; Ilo D; Finney-Hayward T; Zhou W; Phillips C; Gonzalez YS; Shu L; Yao X; Zhou Q; Vermeire S
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2347-2358.e6. PubMed ID: 36464141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
    Akiyama S; Yokoyama K; Yagi S; Shinzaki S; Tsuruta K; Yoshioka S; Sako M; Shimizu H; Kobayashi M; Sakurai T; Nomura K; Shibuya T; Takahara M; Hiraoka S; Sugai K; Yanai S; Yoshida A; Koroku M; Omori T; Saruta M; Matsumoto T; Okamoto R; Tsuchiya K; Fujii T
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1413-1424. PubMed ID: 38494867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
    Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study.
    Kobayashi T; Dignass A; Roblin X; Takatori Y; Kaise T; Oortwijn A; Jamoul C; Hibi T
    Intest Res; 2024 Jun; ():. PubMed ID: 39026439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
    Orbai AM; Ogdie A; Gossec L; Tillett W; Leung YY; Gao J; Trivedi M; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Coates LC
    Rheumatology (Oxford); 2020 Jul; 59(7):1495-1504. PubMed ID: 31624837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filgotinib for moderately to severely active ulcerative colitis.
    Mannucci A; D'Amico F; El Saadi A; Peyrin-Biroulet L; Danese S
    Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):927-940. PubMed ID: 36278878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.